Samrat Pharmachem Ltd (SAMRATPH) — shareholding pattern, promoter holding, financials and share price
About Samrat Pharmachem Ltd (SAMRATPH)
Samrat Pharmachem Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SAMRATPH and on the BSE under scrip code 530125. Its ISIN is INE103E01016.
Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals [1]
Samrat Pharmachem Limited, established in 1992, primarily manufactures and sells chemicals.
A key development was the creation of a subsidiary, Samrat Remedies Limited, focusing on pharmaceutical bulk drugs and chemicals.
Listed peers in Pharmaceuticals: Amwill Health Care Ltd, Curis Lifesciences Ltd, Zenith Drugs Ltd, Veerhealth Care Ltd, Bharat Immunological & Biological Corporation Ltd, Sunil Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹254.01 a share on 10 Jul 2026, Samrat Pharmachem Ltd (SAMRATPH) was valued at a price-to-earnings ratio of -23.64x against an industry P/E of 36.41x and a price-to-book of 1.09x on a book value of ₹232.39 per share as of Mar 2025. Solomo computes return on equity of -4.62% and return on capital employed of -2.46% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -23.64x
- Industry P/E
- 36.41x
- P/B
- 1.09x
- EPS (TTM)
- ₹-10.75
- Book value / share
- ₹232.39
- ROE
- -4.62%
- ROCE
- -2.46%
- ROA
- -2.73%
- Debt / equity
- 0.14x
- Dividend yield
- 0.39%
- EBITDA margin
- -0.45%
- 52-week range
- ₹190 – ₹387.35
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Samrat Pharmachem Ltd (SAMRATPH) reported revenue of ₹290 crore, net profit of ₹-3 crore and earnings per share of ₹-10.71. That compares with revenue of ₹286 crore and net profit of ₹7 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹71.77 crore and net profit ₹-2.04 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 222 | 311 | 282 | 286 | 290 |
| Net profit (₹ cr) | 17 | 17 | 2 | 7 | -3 |
| EPS (₹) | 55.6 | 53.82 | 6.99 | 23.01 | -10.71 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 17.50% | 12.72% | 8.83% | 1.52% |
| Profit growth | 42.09% | 10.92% | -25.48% | 229.17% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 49.09% of Samrat Pharmachem Ltd (SAMRATPH) (unchanged from the previous quarter), foreign institutional investors (FII) hold 3.24%. Market capitalisation was ₹78 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: SANGEETHA S 3.27%, HUF 1.39%, LALIT KUMAR V JAIN 1.22%, SHARAD KANAYALAL SHAH 1.13%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 49.09% | - | 3.24% | - | 50.91% |
| Mar 2026 | 49.09% | - | 3.24% | - | 50.91% |
| Dec 2025 | 49.09% | - | 3.24% | - | 50.91% |
| Sep 2025 | 49.09% | - | 3.24% | - | 50.91% |
| Jun 2025 | 49.09% | - | - | 3.24% | 50.91% |
| Mar 2025 | 49.09% | - | 3.24% | - | 50.91% |
| Dec 2024 | 49.09% | - | 3.24% | - | 50.91% |
| Sep 2024 | 48.95% | - | 3.24% | 0.22% | 51.05% |